
At FDA Rare Disease Day 2026, leaders highlighted new regulatory pathways, faster review programs, and patient-centered innovations accelerating treatments for rare diseases, including NF1 and pediatric cancers. From the Plausible Mechanism Framework to expanded real-world evidence use, the message was clear: Urgency, flexibility, and patient voice are driving rare disease drug development forward.




















